At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Pemetrexed, Carboplatin, and 2 other interventions for Breast Cancer. Completed, enrolled 135 participants across 22 sites in 5 countries.
Detailed Summary
The primary purpose of this study is to help answer the following research questions: * whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast cancer to make the tumor smaller or disappear and for how long * to learn more about the side effects in each chemotherapy combination treatment arm * to assess how participants with advanced breast cancer report health changes while receiving any of the chemotherapy combination arm
Study Details
Timeline
Interventions
600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.